


Immune-Related Adverse Event: Pneumonitis

Pulmonary irAEs have been observed following treatment with immunotherapy and have occurred after a single dose and after as many as 48 treatments. The frequency of pulmonary AEs may be greater with immunotherapy combination therapies than with monotherapy. The majority of cases reported were Grade 1 or Grade 2 and subjects presented with either asymptomatic radiographic changes (eg, focal ground glass opacities, patchy infiltrates) or with symptoms of dyspnoea, cough, or fever. Subjects with reported Grade 3 or Grade 4 pulmonary AEs were noted to have more severe symptoms, more extensive radiographic findings, and hypoxia.



Interrupt SACT immunotherapy until discussed with Acute Oncology Team. Please contact [on-call oncology/haematology team](#) for advice. Ensure that the patient has monitoring/follow up planned with their oncology/immuno-oncology team.

Issue Date: 11 th July 2023	Page 1 of 1	Filename: GAMAPNEUM	Version No: 3.1
Author: Trudy- Jane Guinan	Authorised by: SRG Meeting – Supportive Care & Palliative		Copy No: